EVITA: a tool for the early EValuation of pharmaceutical Innovations with regard to Therapeutic Advantage

New drugs are generally claimed to represent a therapeutic innovation. However, scientific evidence of a substantial clinical advantage is often lacking. This may be the result of using inadequate control groups or surrogate outcomes only in the clinical trials. In view of this, EVITA was developed as a user-friendly transparent tool for the early evaluation of the additional therapeutic value of a new drug.EVITA does not evaluate a new compound...